Schering-Plough reports successful use of Levitra for ED in dyslipidemia patients

Schering-Plough has announced the results of a trial assessing the use of Levitra (vardenafil HCl) in dyslipidemia patients experiencing erectile dysfunction (ED).

At the autumn meeting of the Sexual Medicine Society of North America, the company reported that the compound was found to significantly improve the ability of men with ED and dyslipidemia to have and maintain an erection through throughout intercourse.

The compound was also found to be well-tolerated in patients, with nine per cent experiencing headaches, and five per cent contracting upper respiratory tract infections, compared to one per cent and three per cent of those receiving placebo.

Dr Martin Miner, clinical associate professor of family medicine at Brown University’s Warren Alpert School of Medicine, said: “ED is associated with high cholesterol, yet many physicians are not treating ED, a life-changing condition.”

He added that this study provides evidence that Levitra can treat this condition, even in men with high cholesterol.

In September 2006, Bayer published the results of the Confirmed clinical trial showing that Levitra is “at least as good as Viagra”, with 38.9 per cent of men expressing a preference for the former compound.